IQVIA Reports Third-Quarter 2026 Results • • • • • • • • • Revenue $4,428 million, up 8.0% year-over-year, up 8.6% at constant currency GAAP Net Income $350 million, Adjusted EBITDA $1,032 million, up 8.7% year-over-year GAAP Diluted Earnings per…
IQVIA Reports Third-Quarter 2026 Results
•
•
•
•
•
•
•
•
•
Revenue $4,428 million, up 8.0% year-over-year, up 8.6% at constant currency
GAAP Net Income $350 million, Adjusted EBITDA $1,032 million, up 8.7% year-over-year
GAAP Diluted Earnings per Share $2.10, Adjusted Diluted Earnings per Share $3.34, up 11.3% yearover-year
Commercial Solutions Revenue $1,789 million, up 6.9% year-over-year, up 7.9% at constant currency
R&D Solutions Revenue $2,639 million, up 8.7% year-over-year, up 9.1% at constant currency
R&D Solutions Net New Bookings $3.2 billion, up 15% year-over-year
Operating Cash Flow $825 million, and Free Cash Flow $667 million, representing 120% of Adjusted
Net Income
Raising full-year 2026 guidance for Revenue, Adjusted EBITDA and Adjusted Diluted Earnings per
Share
Investor Day to be held on December 1, 2026
RESEARCH TRIANGLE PARK, N.C. – (BUSINESS WIRE) – October 27, 2026 – IQVIA Holdings Inc. (“IQVIA”)
(NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence
to the life sciences and healthcare industries, today reported financial results for the quarter ended September 30,
2026.
Year-Over-Year Comparisons
As previously disclosed, effective January 1, 2026, the company implemented a new, simplified organizational model
to strengthen collaboration, enhance efficiency, and support continued growth. As a result, the company reports its
results within two segments: Commercial Solutions and Research & Development Solutions (R&DS). In conjunction
with this change, prior period segment amounts have been recast to conform to this reporting structure.
Third-Quarter 2026 Operating Results
"IQVIA delivered another record quarter, with revenue, Adjusted EBITDA and Adjusted Diluted EPS all exceeding the
high end of our expectations," said Ari Bousbib, chairman and CEO of IQVIA. "Multiple demand indicators continue to
validate the strengthening market environment. EBP funding, RFP flow, clinical trial starts, FDA approvals,
outsourcing trends, and pipeline growth across clinical and commercial are all favorable. At the same time, the team's
ongoing excellent execution delivered margin expansion, strong free cash flow, higher win rates that resulted in our
strongest clinical quarterly bookings since 2022, increased penetration of AI-powered solutions with over 400 AI
agents deployed to date, and organic growth acceleration year-over-year to double the rate for commercial and
nearly triple the rate for clinical."
Revenue for the third quarter of $4,428 million increased 8.0% on a reported basis and 8.6% at constant currency,
compared to the third quarter of 2025. Commercial Solutions revenue of $1,789 million increased 6.9% on a reported
basis and 7.9% at constant currency. Research & Development Solutions revenue of $2,639 million grew 8.7% on a
reported basis and 9.1% at constant currency. Excluding reimbursed expenses, R&DS revenue grew 6.8% on a
reported basis.
Third quarter net new bookings were $3.2 billion, up 15% year-over-year, representing a book-to-bill ratio of 1.2x.
Last-twelve-month net new bookings were $11.7 billion, up 14% year-over-year.
As previously discussed, the company conducted a detailed review of inactive trials in our backlog estimates. This
review resulted in an adjustment to backlog of approximately $2.1 billion. The adjustment has no impact on historical
financial results, 2026 guidance, book-to-bill, or next-twelve-month revenue from backlog estimates. As of
September 30, 2026, R&DS contracted backlog was $32.6 billion. The company expects approximately $9.4 billion of
this backlog to convert to revenue in the next twelve months, representing growth of 10% year-over-year.
1
Third-quarter GAAP Net Income was $350 million and GAAP Diluted Earnings per Share was $2.10. Adjusted
EBITDA was $1,032 million, up 8.7% year-over-year. Adjusted Net Income was $557 million and Adjusted Diluted
Earnings per Share was $3.34, up 11.3% year-over-year.
Year-to-Date 2026 Operating Results
Revenue for the first nine months of 2026 was $12,947 million, up 8.4% on a reported basis and 7.7% at constant
currency, compared to the first nine months of 2025. Commercial Solutions revenue of $5,336 million increased 9.0%
on a reported basis and 8.3% at constant currency. Research & Development Solutions revenue of $7,611 million
increased 8.0% on a reported basis and 7.4% at constant currency.
GAAP Net Income was $880 million and GAAP Diluted Earnings per Share was $5.24. Adjusted EBITDA was $2,958
million, up 7.9% year-over-year. Adjusted Net Income was $1,576 million and Adjusted Diluted Earnings per Share
was $9.38, up 10.4% year-over-year.
Financial Position
As of September 30, 2026, cash and cash equivalents were $2,249 million and debt was $16,067 million, resulting in
net debt of $13,818 million. IQVIA’s Net Leverage Ratio was 3.45x trailing twelve-month Adjusted EBITDA. For the
third quarter, Operating Cash Flow was $825 million, and Free Cash Flow was $667 million, representing 120% of
Adjusted Net Income.
Full-Year 2026 Guidance
The company is raising its full-year 2026 guidance for revenue to be between $17,350 million and $17,500 million, for
Adjusted EBITDA to be between $4,025 million and $4,055 million and for Adjusted Diluted Earnings per Share to be
between $12.90 and $13.00.
This revenue guidance now anticipates 250 basis points of contribution from acquisitions, including acquisitions the
company expects to complete by the end of the year, and approximately 20 basis points of tailwind from foreign
exchange.
All financial guidance assumes foreign currency exchange rates as of October 26, 2026 remain in effect for the
forecast period.
Investor Day
IQVIA will host an Investor Day on Tuesday, December 1, 2026. Management will provide an update on the business,
with presentations from members of IQVIA’s senior executive team starting at 9:00 a.m. ET and concluding at
approximately 12:30 p.m. ET. Registration is required to attend the event. More information on the event will be
available shortly on the IQVIA Investor Relations website at http://ir.iqvia.com.
Webcast & Conference Call Details
IQVIA will host a conference call at 9:00 a.m. Eastern Time today to discuss its third-quarter 2026 results and fullyear 2026 guidance. To listen to the event and view the presentation slides via webcast, join from the IQVIA Investor
Relations website at http://ir.iqvia.com. To participate in the conference call, interested parties must register in
advance by clicking on this link. Following registration, participants will receive a confirmation email containing details
on how to join the conference call, including the dial-in and a unique passcode and registrant ID. At the time of the
live event, registered participants connect to the call using the information provided in the confirmation email and will
be placed directly into the call.
2
About IQVIA
IQVIA (NYSE:IQV) is a leading global provider of clinical research services, commercial insights and healthcare
intelligence to the life sciences and healthcare industries. IQVIA’s portfolio of solutions are powered by IQVIA
Connected Intelligence™ to deliver actionable insights and services built on high-quality health data, Healthcaregrade AI®, advanced analytics, the latest technologies and extensive domain expertise. IQVIA is committed to using
artificial intelligence responsibly, with AI-powered capabilities built on best-in-class approaches to privacy, regulatory
compliance and patient safety, and delivering AI to the high standards of trust, scalability and precision demanded by
the industry. With approximately 95,000 employees in over 100 countries, including experts in healthcare, life
sciences, data science, technology and operational excellence, IQVIA is dedicated to accelerating the development
and commercialization of innovative medical treatments to help improve patient outcomes and population health
worldwide.
IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacyenhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a
scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and
therapy needed for better outcomes. IQVIA’s insights and execution capabilities help biotech, medical device and
pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders
tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their
path toward cures. To learn more, visit www.iqvia.com.
3
Cautionary Statements Regarding Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the federal securities laws, including
Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as
amended, including, without limitation, our full-year 2026 guidance. In this context, forward-looking statements often
address expected future business and financial performance and financial condition, and often contain words such as
“expect,” “assume,” “anticipate,” “intend,” “plan,” “forecast,” “believe,” “seek,” “see,” “will,” “would,” “target,” similar
expressions, and variations or negatives of these words that are intended to identify forward-looking statements,
although not all forward-looking statements contain these identifying words. Actual results may differ materially from
our expectations due to a number of factors, including, but not limited to, the following: business disruptions caused
by natural disasters, pandemics, and the public health policy response to any outbreak, and international conflicts or
other disruptions outside of our control; most of our contracts may be terminated on short notice, and we may lose or
experience delays with large client contracts or be unable to enter into new contracts; the market for our services
may not grow as we expect; we may be unable to successfully develop and market new services or enter new
markets; imposition of restrictions on our use of data by data suppliers or their refusal to license data to us; any
failure by us to comply with contractual, regulatory or ethical requirements under our contracts, including current or
future changes to data protection and privacy laws; breaches or misuse of our or our outsourcing partners’ security or
communications systems; failure to meet our productivity or business transformation objectives; failure to
successfully invest in growth opportunities; our ability to protect our intellectual property rights and our susceptibility
to claims by others that we are infringing on their intellectual property rights; the expiration or inability to acquire third
party licenses for technology or intellectual property; any failure by us to accurately and timely price and formulate
cost estimates for contracts, or to document change orders; hardware and software failures, delays in the operation
of our computer and communications systems or the failure to implement system enhancements; the rate at which
our backlog converts to revenue; our ability to acquire, develop and implement technology necessary for our
business; consolidation in the industries in which our clients operate; risks related to client or therapeutic
concentration; government regulators or our customers may limit the number or scope of indications for medicines
and treatments or withdraw products from the market, and government regulators may impose new regulatory
requirements or may adopt new regulations affecting the biopharmaceutical industry; the risks associated with
operating on a global basis, including currency or exchange rate fluctuations and legal compliance, including anticorruption laws; risks related to the enactment of legislation or the imposition of regulations or other restrictions or
actions by governments that create business uncertainty and have the potential to limit trade; changes in accounting
standards; general economic conditions in the markets in which we operate, including financial market conditions,
inflation, and risks related to sales to government entities; the impact of changes in tax laws and regulations; and our
ability to successfully integrate, and achieve expected benefits from, our acquired businesses. In addition, we may
not achieve the expected benefits of our reorganized business segment structure. For a further discussion of the
risks relating to our business, see the “Risk Factors” in our annual report on Form 10-K for the fiscal year ended
December 31, 2025, filed with the Securities and Exchange Commission (the "SEC"), as such factors may be
amended or updated from time to time in our subsequent periodic and other filings with the SEC, which are
accessible on the SEC’s website at www.sec.gov. These factors should not be construed as exhaustive and should
be read in conjunction with the other cautionary statements that are included in this release and in our filings with the
SEC. We assume no obligation to update any such forward-looking statement after the date of this release, whether
as a result of new information, future developments or otherwise.
4
Note on Non-GAAP Financial Measures
This release includes information based on financial measures that are not recognized under generally accepted
accounting principles in the United States ("GAAP"), such as Adjusted EBITDA, Adjusted Net Income, Adjusted
Diluted Earnings per Share, Gross Leverage Ratio, Net Leverage Ratio and Free Cash Flow. Non-GAAP financial
measures are presented only as a supplement to the company’s financial statements based on GAAP. Non-GAAP
financial information is provided to enhance understanding of the company’s financial performance, but none of these
non-GAAP financial measures are recognized terms under GAAP, and non-GAAP measures should not be
considered in isolation from, or as a substitute analysis for, the company’s results of operations as determined in
accordance with GAAP. The company uses non-GAAP measures in its operational and financial decision making,
and believes that it is useful to exclude certain items in order to focus on what it regards to be a more meaningful
indicator of the underlying operating performance of the business. For example, the company excludes all the
amortization of intangible assets associated with acquired customer relationships and backlog, databases, noncompete agreements, trademarks and trade names from non-GAAP expense and income measures as such
amounts can be significantly impacted by the timing and size of acquisitions. Although we exclude amortization of
acquired intangible assets from our non-GAAP expenses, we believe that it is important for investors to understand
that revenue generated from such intangibles is included within revenue in determining net income. As a result,
internal management reports feature non-GAAP measures which are also used to prepare strategic plans and annual
budgets and review management compensation. The company also believes that investors may find non-GAAP
financial measures useful for the same reasons, although investors are cautioned that non-GAAP financial measures
are not a substitute for GAAP disclosures.
The non-GAAP financial measures are not presented in accordance with GAAP. Please refer to the schedules
attached to this release for reconciliations of non-GAAP financial measures contained herein to the most directly
comparable GAAP measures. Our full-year 2026 guidance measures (other than revenue) are provided on a nonGAAP basis without a reconciliation to the most directly comparable GAAP measure because the company is unable
to predict with a reasonable degree of certainty certain items contained in the GAAP measures without unreasonable
efforts. For the same reasons, the company is unable to address the probable significance of the unavailable
information. Such items include, but are not limited to, acquisition related expenses, restructuring and related
expenses, stock-based compensation and other items not reflective of the company's ongoing operations.
Non-GAAP measures are frequently used by securities analysts, investors and other interested parties in their
evaluation of companies comparable to the company, many of which present non-GAAP measures when reporting
their results. Non-GAAP measures have limitations as an analytical tool. They are not presentations made in
accordance with GAAP, are not measures of financial condition or liquidity and should not be considered as an
alternative to profit or loss for the period determined in accordance with GAAP or operating cash flows determined in
accordance with GAAP. Non-GAAP measures are not necessarily comparable to similarly titled measures used by
other companies. As a result, you should not consider such performance measures in isolation from, or as a
substitute analysis for, the company’s results of operations as determined in accordance with GAAP.
IQVIAFIN
#
5
Table 1
IQVIA HOLDINGS INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(preliminary and unaudited)
Three Months Ended
September 30,
2026
2025
(in millions, except per share data)
Revenues
Cost of revenues, exclusive of depreciation and amortization
Selling, general and administrative expenses
Depreciation and amortization
Restructuring costs
Income from operations
Interest income
Interest expense
Loss on extinguishment of debt
Other (income) expense, net
Income before income taxes and equity in earnings (losses) of
unconsolidated affiliates
Income tax expense
Income before equity in earnings (losses) of unconsolidated
affiliates
Equity in earnings (losses) of unconsolidated affiliates
Net income
Net income attributable to noncontrolling interests
Net income attributable to IQVIA Holdings Inc.
Earnings per share attributable to common stockholders:
Basic
Diluted
Weighted average common shares outstanding:
Basic
Diluted
$
Nine Months Ended
September 30,
2026
2025
4,428 $
2,930
569
321
36
572
(12)
203
—
(5)
4,100 $
2,727
514
286
20
553
(13)
189
—
(31)
12,947 $
8,659
1,645
901
150
1,592
(29)
592
3
11
11,946
7,952
1,531
827
81
1,555
(34)
536
4
(5)
386
76
408
76
1,015
195
1,054
193
$
310
42
352
(2)
350 $
332
—
332
(1)
331 $
820
65
885
(5)
880 $
861
(14)
847
(1)
846
$
$
2.13 $
2.10 $
1.94 $
1.93 $
5.29 $
5.24 $
4.90
4.86
164.7
167.0
170.2
171.7
166.4
168.0
172.6
174.1
6
Table 2
IQVIA HOLDINGS INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(preliminary and unaudited)
(in millions, except per share data)
September 30, 2026
December 31, 2025
ASSETS
Current assets:
Cash and cash equivalents
$
Trade accounts receivable and unbilled services, net
Prepaid expenses
Income taxes receivable
Investments in debt, equity and other securities
Other current assets and receivables
Total current assets
Property and equipment, net
Operating lease right-of-use assets
Investments in debt, equity and other securities
Investments in unconsolidated affiliates
Goodwill
Other identifiable intangibles, net
Deferred income taxes
Deposits and other assets, net
Total assets
$
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable and accrued expenses
$
Unearned income
Income taxes payable
Current portion of long-term debt
Other current liabilities
Total current liabilities
Long-term debt, less current portion
Deferred income taxes
Operating lease liabilities
Other liabilities
Total liabilities
Commitments and contingencies
Stockholders’ equity:
Common stock and additional paid-in capital, 400.0 shares authorized as of
September 30, 2026 and December 31, 2025, $0.01 par value, 259.8 shares issued
and 164.8 shares outstanding as of September 30, 2026; 259.1 shares issued and
169.6 shares outstanding as of December 31, 2025
Retained earnings
Treasury stock, at cost, 95.0 and 89.5 shares as of September 30, 2026 and
December 31, 2025, respectively
Accumulated other comprehensive loss
Equity attributable to IQVIA Holdings Inc.’s stockholders
Noncontrolling interests
Total stockholders’ equity
Total liabilities and stockholders’ equity
$
2,249 $
3,293
210
39
173
487
6,451
534
313
86
438
16,900
4,738
408
606
30,474 $
1,980
3,400
162
27
161
519
6,249
533
290
108
324
16,616
4,962
357
505
29,944
3,676 $
2,313
171
1,244
373
7,777
14,823
157
247
679
23,683
3,751
2,118
140
1,840
489
8,338
13,884
179
225
688
23,314
11,576
8,305
11,378
7,425
(12,315)
(906)
6,660
131
6,791
30,474 $
(11,357)
(943)
6,503
127
6,630
29,944
7
Table 3
IQVIA HOLDINGS INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(preliminary and unaudited)
Nine Months Ended September 30,
2026
2025
(in millions)
Operating activities:
Net income
Adjustments to reconcile net income to cash provided by operating activities:
Depreciation and amortization
Amortization of debt issuance costs and discount
Stock-based compensation
(Earnings) losses from unconsolidated affiliates
Loss (gain) on investments, net
Benefit from deferred income taxes
Changes in operating assets and liabilities:
Change in accounts receivable, unbilled services and unearned income
Change in other operating assets and liabilities
Net cash provided by operating activities
Investing activities:
Acquisition of property, equipment and software
Acquisition of businesses, net of cash acquired
Sales of marketable securities, net
Investments in unconsolidated affiliates, net of payments received
Investments in debt and equity securities
Proceeds from sale of property, equipment and software
Other
Net cash used in investing activities
Financing activities:
Proceeds from issuance of debt
Payment of debt issuance costs
Repayment of debt and principal payments on finance leases
Proceeds from revolving credit facility
Repayment of revolving credit facility
Payments related to employee stock incentive plans
Repurchase of common stock
Distributions to noncontrolling interests, net
Contingent consideration and deferred purchase price payments
Other
Net cash used in financing activities
Effect of foreign currency exchange rate changes on cash
Increase in cash and cash equivalents
Cash and cash equivalents at beginning of period
Cash and cash equivalents at end of period
$
$
885 $
847
901
17
243
(65)
7
(97)
827
17
187
14
(20)
(132)
341
(231)
2,001
442
(263)
1,919
(483)
(589)
3
(67)
—
—
—
(1,136)
(429)
(798)
2
(28)
(20)
75
(3)
(1,201)
3,758
(49)
(2,458)
1,350
(2,150)
(43)
(950)
(1)
(17)
(9)
(569)
(27)
269
1,980
2,249 $
3,985
(34)
(2,676)
1,375
(2,200)
(66)
(1,032)
—
(26)
(11)
(685)
79
112
1,702
1,814
8
Table 4
IQVIA HOLDINGS INC. AND SUBSIDIARIES
NET INCOME TO ADJUSTED EBITDA RECONCILIATION
(preliminary and unaudited)
Three Months Ended
September 30,
2026
2025
(in millions)
Net Income Attributable to IQVIA Holdings Inc.
Provision for income taxes
Depreciation and amortization
Interest expense, net
(Income) loss in unconsolidated affiliates
Income from noncontrolling interests
Stock-based compensation
Other expense (income), net (1)
Loss on extinguishment of debt
Restructuring and related expenses (2)
Acquisition related expenses
Adjusted EBITDA
(1)
(2)
$
$
350 $
76
321
191
(42)
2
83
2
—
41
8
1,032 $
Nine Months Ended
September 30,
2026
2025
331 $
76
286
176
—
1
55
(21)
—
30
15
949 $
880 $
195
901
563
(65)
5
243
43
3
161
29
2,958 $
846
193
827
502
14
1
187
23
4
114
31
2,742
Reflects certain non-operating income items, revaluations of contingent consideration and certain non-recurring expenses.
Reflects restructuring costs as well as accelerated expenses related to lease exits.
9
Table 5
IQVIA HOLDINGS INC. AND SUBSIDIARIES
NET INCOME TO ADJUSTED NET INCOME RECONCILIATION
(preliminary and unaudited)
Three Months Ended
September 30,
2026
2025
(in millions, except per share data)
Net Income Attributable to IQVIA Holdings Inc.
Provision for income taxes
Purchase accounting amortization (1)
(Income) loss in unconsolidated affiliates
Income from noncontrolling interests
Stock-based compensation
Other expense (income), net (2)
Loss on extinguishment of debt
Restructuring and related expenses (3)
Acquisition related expenses
Adjusted Pre Tax Income
Adjusted tax expense
Income from noncontrolling interests
Adjusted Net Income
Adjusted earnings per share attributable to common
stockholders:
Basic
Diluted
Weighted average common shares outstanding:
Basic
Diluted
(1)
(2)
(3)
$
Nine Months Ended
September 30,
2026
2025
$
350 $
76
163
(42)
2
83
2
—
41
8
683 $
(124)
(2)
557 $
331 $
76
138
—
1
55
(21)
—
30
15
625 $
(109)
(1)
515 $
880 $
195
436
(65)
5
243
43
3
161
29
1,930 $
(349)
(5)
1,576 $
846
193
394
14
1
187
23
4
114
31
1,807
(326)
(1)
1,480
$
$
3.38 $
3.34 $
3.03 $
3.00 $
9.47 $
9.38 $
8.57
8.50
164.7
167.0
170.2
171.7
166.4
168.0
172.6
174.1
$
Reflects all the amortization of acquired intangible assets.
Reflects certain non-operating income items, revaluations of contingent consideration and certain non-recurring expenses.
Reflects restructuring costs as well as accelerated expenses related to lease exits.
10
Table 6
IQVIA HOLDINGS INC. AND SUBSIDIARIES
NET CASH PROVIDED BY OPERATING ACTIVITIES TO FREE CASH FLOW RECONCILIATION
(preliminary and unaudited)
Three Months Ended
September 30,
2026
2025
(in millions)
Net Cash provided by Operating Activities
Acquisition of property, equipment and software
Free Cash Flow
$
$
825 $
(158)
667 $
908 $
(136)
772 $
Nine Months Ended
September 30,
2026
2025
2,001 $
(483)
1,518 $
1,919
(429)
1,490
11
Table 7
IQVIA HOLDINGS INC. AND SUBSIDIARIES
CALCULATION OF GROSS AND NET LEVERAGE RATIOS
AS OF SEPTEMBER 30, 2026
(preliminary and unaudited)
(in millions)
Gross Debt, net of Unamortized Discount and Debt Issuance Costs, as of September 30, 2026
Net Debt as of September 30, 2026
Adjusted EBITDA for the twelve months ended September 30, 2026
Gross Leverage Ratio (Gross Debt/LTM Adjusted EBITDA)
Net Leverage Ratio (Net Debt/LTM Adjusted EBITDA)
$
$
$
16,067
13,818
4,004
4.01x
3.45x